SEC Form 4 · accession 0001127602-17-031441
TOMPKINS FINANCIAL CORP · TMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory J Hartz
Officer — EVP, Pres.&CEO Tompkins Trust
Period of report
Nov 3, 2017
Accepted (ET)
Nov 7, 2017 · 12:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005817
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 3, 2017 | M | 520 | $40.60 | A | 18,628 | D | |
| Common StockF1 | Nov 3, 2017 | F | 364 | $85.20 | D | 18,264 | D | |
| Common Stock | Nov 3, 2017 | M | 590 | $49.22 | A | 18,854 | D | |
| Common StockF1 | Nov 3, 2017 | F | 447 | $85.20 | D | 18,407 | D | |
| Common Stock | Nov 3, 2017 | M | 892 | $37.00 | A | 19,299 | D | |
| Common StockF1 | Nov 3, 2017 | F | 602 | $85.20 | D | 18,697 | D | |
| Common StockF2 | Nov 4, 2017 | F | 84 | $85.20 | D | 18,613 | D | |
| Common Stock | holding | — | — | — | 3,932 | I | by 401(k)/ISOP | |
| Common Stock | holding | — | — | — | 2,400 | I | by ESOP |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation Rights (SAR)F3 | $40.60 | Nov 3, 2017 | M | 520 | D | — | May 3, 2023 | Common Stock | 520 | 1,497 | D |
| Stock Appreciation Rights (SAR)F3 | $49.22 | Nov 3, 2017 | M | 590 | D | — | Nov 21, 2024 | Common Stock | 590 | 2,885 | D |
| Stock Appreciation Rights (SAR)F3 | $37.00 | Nov 3, 2017 | M | 892 | D | — | Aug 19, 2021 | Common Stock | 892 | 788 | D |
Explanation of responses
- F1Shares withheld for Option cost and taxes
- F2Deemed disposition of shares to the Issuer to pay for taxes upon vesting of restricted stock.
- F3Stock Appreciation Rights (SARs) were granted pursuant to the Tompkins Financial Corporation 2009 Equity Plan. SARs have a seven year vesting schedule with 0% vesting in year one, 17% vesting in years two through six, and 15% vesting in year seven. When exercised, the SARs will be settled in Common Stock of the Company. The grant will expire ten years from the date of the grant.